查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500198

非專利藥注射劑市場：按產品、類型、應用、分銷管道分類 - 2024-2030 年全球預測

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年非專利藥市場規模為331.2億美元，2024年達365.8億美元，到2030年將達到672.2億美元，預計複合年成長率為10.64%。

非專利藥注射劑是透過注射給藥的非品牌藥物，具有與品牌藥物相同的活性成分、規格、劑型、給藥途徑、品質、性能特徵和預期用途。通常在原產品專利到期後出售。非專利藥注射劑透過提供具有成本效益的品牌藥物替代品，有助於節省醫療費用並為患者提供便利。對更實惠的藥物的需求不斷成長，以及由於幾種品牌注射劑的專利到期而導致學名藥進入市場，推動了非專利藥注射劑市場的發展。世界各國政府的成本控制政策也支持普及具有成本效益的非專利藥注射劑。此外，需要注射藥物治療的慢性疾病的增加也支持了市場的成長。儘管成長前景廣闊，但市場在維持高品質標準方面面臨挑戰，如果管理不當，可能會導致召回和聲譽受損。此外，市場競爭激烈且價格下降，這可能會阻礙非專利藥注射劑的採用。然而，專注於先進藥物輸送系統、生物相似藥開發、永續生產以及提高產品穩定性和保存期限的配方進步為市場擴張提供了有利可圖的機會。

主要市場統計
基準年[2023] 331.2億美元
預計年份 [2024] 365.8億美元
預測年份 [2030] 672.2億美元
複合年成長率（%） 10.64%

區域洞察

美洲尤其是美國的非專利藥注射劑市場正在經歷顯著成長。由於品牌藥物的專利到期、政府努力最大限度地降低醫療成本以及慢性病的增加，該地區對負擔得起的學名藥的需求正在迅速增加。除了發達的醫療保健產業外，美洲地區也受惠於競爭激烈的市場格局，許多參與者不斷努力推出新產品和具成本效益的製造流程。歐洲、中東和非洲 (EMEA) 地區的非專利藥注射劑市場正在穩步成長。這一業績是由旨在促進學名藥使用和對生物相似藥的重視的政府支持性衛生政策所推動的。雖然歐洲市場尤其受益於確保高品質產品的嚴格監管標準，但成本效益仍然是非專利藥注射劑普及的驅動力。隨著醫療基礎設施的改善和藥物取得的增加，中東和非洲的市場正在穩步發展。非專利藥注射藥領域目前在亞太（Asia-Pacific）地區正在迅速擴張。印度和中國因其龐大的人口基數、不斷上漲的醫療成本以及政府對學名藥生產的支持政策而成為這一成長的主要貢獻者。該地區還擁有大量學名藥生產商，支持了當地市場的成長。此外，慢性病盛行率的不斷上升以及新興國家加強醫療保健系統的共同努力，為亞太地區非專利藥注射劑市場的成長奠定了堅實的基礎。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在非專利藥注射劑市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對非專利藥注射劑市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

戰略分析和建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在非專利藥注射劑市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和對具有成本效益的藥物的需求
      • 專利到期增加並重視引進學名藥
      • 政府對學名藥和注射劑的有利核准
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 正在進行的與非專利藥注射藥物相關的研究和開發活動
      • 非專利藥注射劑製造的長期戰略合作夥伴關係
    • 任務
      • 對注射品質和製造差異的擔憂
  • 市場區隔分析
    • 產品：由於可用性和熟悉度，各個治療領域小分子注射劑的消費量增加
    • 類型：在新的具有成本效益的治療方法的研究和開發中對非專利細胞激素和單株抗體的需求持續成長
    • 應用：非專利藥注射劑在心臟病學和腫瘤學領域的顯著優勢需要長期和永續的藥物成本
    • 分銷管道：網路商店因其便利性和有競爭力的價格而越來越受歡迎。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章非專利藥市場：依產品

  • 聚合物注射
  • 低分子注射液

第7章非專利藥注射劑市場：按類型

  • 細胞激素
  • 胰島素
  • 單株抗體
  • 疫苗

第8章非專利藥注射劑市場：依應用分類

  • 心臟病學
  • 糖尿病
  • 免疫學
  • 腫瘤學

第9章非專利藥注射劑市場：依通路

  • 醫院藥房
  • 網路處方箋店
  • 零售藥房

第10章美洲非專利用學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區非專利藥注射劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲非專利藥注射劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Gland Pharma 獲得美國FDA核准注射非專利藥
    • Meitheal Pharmaceuticals 宣布擴大非專利藥注射劑產品組合
    • Endo 推出 Noxafil（泊沙康唑）注射液的首個非專利藥
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-C002B1C997E0

[180 Pages Report] The Generic Injectables Market size was estimated at USD 33.12 billion in 2023 and expected to reach USD 36.58 billion in 2024, at a CAGR 10.64% to reach USD 67.22 billion by 2030.

Generic injectables are non-branded pharmaceuticals that are administered by injection and have the same active ingredients, strength, dosage form, route of administration, quality, performance characteristics, and intended use as their branded counterparts. They are typically marketed after the original branded product's patent protection has expired. Generic injectables offer a cost-effective alternative to brand-name drugs, thereby contributing to healthcare savings and increased accessibility for patients. The generic injectables market is fueled by the increasing demand for more affordable pharmaceuticals and the expiration of patents for multiple branded injectables, which allows generic versions to enter the market. Cost-containment policies by governments worldwide also drive the uptake of cost-effective generic injectables. In addition, the rise in the prevalence of chronic diseases that require injectable drugs for treatment supports the market growth. Despite the promising growth, the market faces challenges due to maintaining high-quality standards, which, if not adequately managed, can lead to recalls and reputational damage. Furthermore, the market is subject to intense competition and price erosion, which can hinder the adoption of generic injectables. However, research focusing on advanced drug delivery systems, biosimilar development, sustainable production, and formulation advancements to improve product stability and storage presents lucrative opportunities for market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 33.12 billion
Estimated Year [2024] USD 36.58 billion
Forecast Year [2030] USD 67.22 billion
CAGR (%) 10.64%

Regional Insights

The market for generic injectables in the Americas, and particularly in the United States, has seen significant growth. The expiration of patents for branded drugs, government initiatives to minimize healthcare costs, and the rising prevalence of chronic diseases have resulted in a surging need for affordable generic alternatives in this region. The Americas region benefits from a well-developed healthcare sector and a competitive market landscape where numerous players are constantly engaged in the introduction of new products and cost-effective manufacturing processes. The Europe, Middle East, and Africa (EMEA) region has experienced steady growth in the generic injectables market. This performance is facilitated by supportive governmental health policies aimed at promoting the use of generics, as well as an emphasis on biosimilars. The European market, in particular, benefits from stringent regulatory standards that ensure high-quality products, while cost-effectiveness remains a driving factor behind the widespread adoption of generic injectables. In the Middle East and Africa, the market is steadily evolving with the improving healthcare infrastructure and increased accessibility to medication. The Asia-Pacific (APAC) region is currently witnessing rapid expansion in the generic injectables sector. India and China, with their vast population base, increasing healthcare expenditure, and supportive government policies for generic medicine production, are contributing significantly to this growth. The region also hosts a significant number of generic drug manufacturers, which bolster the local market growth. Additionally, the growing incidence of chronic conditions, coupled with a concerted effort to enhance healthcare systems in emerging economies, provides a robust platform for the growth of the generic injectables market in APAC.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Generic Injectables Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Prevalence of chronic diseases and need for cost-effective medications
      • Increasing patent expirations and emphasis on adopting generic drugs
      • Favorable government approvals for generic drugs & injectables
    • Market Restraints
      • Preference for branded drugs by patients and physicians
    • Market Opportunities
      • Ongoing R&D activities associated with generic injectable drugs
      • Strategic long-term partnerships to manufacture generic injectables
    • Market Challenges
      • Concerns associated with injectable quality and manufacturing variability
  • Market Segmentation Analysis
    • Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Generic Injectables Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Generic Injectables Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Gland Pharma gets USFDA nod for generic injectable

Gland Pharma announced its approval from the US FDA to market its generic version of Angiotensin II Injection, presented in a 2.5 mg/mL single-dose vial. The company's advancements underscore its commitment to enhancing its portfolio in the generic injectables market, ensuring the availability of essential medications within the healthcare system. [Published On: 2023-11-15]

Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products

Meitheal Pharmaceuticals, Inc., part of the fully integrated generic injectables field, has significantly broadened its market offerings through a recent deal orchestrated by Hong Kong King-Friend Industry Co., Ltd. (HKF), their parent entity. The asset purchase agreement detailed by the two organizations leads to an impressive uptick in Meitheal's generic injectable repertoire. [Published On: 2023-10-04]

Endo Launches First Generic Version of Noxafil (posaconazole) Injection

Endo International plc's subsidiary Par Sterile Products has launched the U.S. market's inaugural generic form of Merck's Noxafil with its posaconazole injection (18 mg/mL), following the U.S. Food and Drug Administration's approval of their Abbreviated New Drug Application. This is a significant milestone for Endo, highlighting its commitment to expanding treatment options for healthcare professionals, enhancing its offerings, and affirming its status as a dependable provider of quality pharmaceuticals. [Published On: 2023-06-29]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Generic Injectables Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eugia US LLC, Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Large Molecule Injectables
    • Small Molecule Injectables
  • Type
    • Cytokines
    • Insulin
    • Monoclonal Antibodies
    • Vaccines
  • Application
    • Cardiology
    • Diabetes
    • Immunology
    • Oncology
  • Distribution Channel
    • Hospital Pharmacy
    • Online Prescription Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Cytokines
  • 7.3. Insulin
  • 7.4. Monoclonal Antibodies
  • 7.5. Vaccines

8. Generic Injectables Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Diabetes
  • 8.4. Immunology
  • 8.5. Oncology

9. Generic Injectables Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Prescription Stores
  • 9.4. Retail Pharmacy

10. Americas Generic Injectables Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Injectables Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Gland Pharma gets USFDA nod for generic injectable
    • 13.3.2. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
    • 13.3.3. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY